317 research outputs found
Recommended from our members
Nidi Gratis in Lombardia. Attuazione e risultati
âNidi Gratisâ initiative, now in its fourth year, was introduced by Lombardy Region on an experimental basis in April 2016 as part of the âReddito di Cittadinanzaâ program and was then confirmed for the following years thanks to a continuous investment of resources, including the use of European funds (POR FSE 2014-2020 Program) starting from the second annuity. The purpose of the initiative is to support the recipient families living in condition of economic and social vulnerability, excluding familiesâ cash outflows for the payment of the tuition costs of nursery schools (0-3 years) in the partaking municipalities, thus facilitating access to child services and answering to work-life balance needs. This research was promoted by the âComitato Paritetico di Controllo e Valutazione del Consiglio regionale della Lombardiaâ and aims to evaluate the implementation and results of the initiative in the region. The sources used to conduct this analysis were different: (1) structured questionnaire by PoliS-Lombardia sent to all the nursery schools in the region; (2) stakeholders interviews conducted by PoliS-Lombardia; (3) customer satisfaction surveys available in Lombardy Region Open Data; (4) comparison of the employment status of the parents between T0 (declaration of the family unit economic situation at the beginning of the year) and T1 (Nidi Gratis application form); (5) further assessments of Lombardy Region performance conducted by PoliS-Lombardia.
The main results indicate the strengths and weaknesses of âNidi Gratisâ, considering both the economic, managerial and administrative data related to the implementation of the initiatives, and stakeholdersâ personal experience
Depression in Diabetic Patients: What Is the Link With Eating Disorders? Results of a Study in a Representative Sample of Patients With Type 1 Diabetes
Comorbidity between diabetes and depression, and diabetes and eating disorders (ED) conveys significant diagnostic, clinical and therapeutic implications. The present study was conducted on a sample of adult outpatients affected by Type 1 Diabetes (T1DM) to assess lifetime prevalence of ED; current prevalence of depression and Disturbed Eating Behaviors (DEB) and their impact on glycemic control. We hypothesized that patients with depression would have higher rates of lifetime ED and current DEB. We hypothesized a significant and independent association between DEB and the prevalence of depression
Measurement of the ratios of branching fractions and
The ratios of branching fractions
and are measured, assuming isospin symmetry, using a
sample of proton-proton collision data corresponding to 3.0 fb of
integrated luminosity recorded by the LHCb experiment during 2011 and 2012. The
tau lepton is identified in the decay mode
. The measured values are
and
, where the first uncertainty is
statistical and the second is systematic. The correlation between these
measurements is . Results are consistent with the current average
of these quantities and are at a combined 1.9 standard deviations from the
predictions based on lepton flavor universality in the Standard Model.Comment: All figures and tables, along with any supplementary material and
additional information, are available at
https://cern.ch/lhcbproject/Publications/p/LHCb-PAPER-2022-039.html (LHCb
public pages
Assessment of eating disorders with the diabetes eating problems survey â revised (DEPS-R) in a representative sample of insulin-treated diabetic patients: a validation study in Italy
Molecular characterization of monoamine oxidase in zebrafish (Danio rerio)
Monoamine oxidase (MAO) is responsible for the degradation of a number of neurotransmitters and other biogenic amines. In terrestrial vertebrates, two forms of the enzyme, named MAO A and B, were found in which mammals are coded by two similar but distinct genes. In teleosts, the biochemical data obtained so far indicate that enzyme activity is due to a single form, whose sequence, obtained for trout, displays 70% identity with mammal MAO A and B. In this paper, we carried out an investigation of zebrafish MAO (Z-MAO) to shed further light on the nature of the MAO form present in aquatic vertebrates. Sequencing studies have revealed an open reading frame 522-amino-acids long with MW 58.7 kDa, displaying 84% identity with trout MAO and about 70% identity with mammal MAO A and MAO B. Analysis of the sequence and of the predicted secondary structure shows that also in Z-MAO principal domains characterizing the MAOs are present. The domain linking the FAD is very well conserved, while the transmembrane domain sequence linking the enzyme to the external mitochondrial membrane does not appear to be conserved even with respect to trout MAO. Comparison with the amino acids which, according to the human MAO B and rat MAO A models, line the substrate-binding site shows that in Z-MAO, several residues (V172, N173, F200, L327) differ from MAO B but are similar or identical to the corresponding ones present in rat MAO A, as well as in trout MAO. A three-dimensional model is reported of the substrate-binding site of Z-MAO obtained by comparative modeling. Our observations support the hypothesis that the MAO form present in aquatic vertebrates is a MAO A-like form. Experiments performed to test the effect of selective MAO A (clorgyline) and MAO B (deprenyl) inhibitors on the enzyme's activity in liver and brain confirm the presence of a single form of MAO in zebrafish. (C) 2004 Elsevier Inc. All rights reserved
Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease
Incidence, predictors and effect of discontinuation of long-acting bronchodilators on the risk of death or hospital admission among adults with Chronic Obstructive Pulmonary Disease (COPD) were assessed in a large population-based prospective study carried out by linking Italian healthcare utilization databases. Specifically, the cohort of 17,490 beneficiaries of the National Health Service in the Italian Region of Lombardy, aged 40\ua0years or older, who started long-acting bronchodilators therapy during 2005-2008 was followed from first dispensation until 2012. During this period, patients who experienced discontinuation of long-acting bronchodilators were identified. Hospitalizations for COPD and deaths for any cause (composite clinical outcome) were also identified during follow-up. A Cox proportional hazards model was fitted to identify predictors of discontinuation. The case-crossover design was used to assess the implications of treatment discontinuation on the clinical outcome risk. Cumulative incidences of discontinuation were, respectively, 67%, 80%, and 92% at 6\ua0months, 1\ua0year, and 5\ua0years since initial treatment. Significant predictors of discontinuation were female gender, younger age, starting treatment with fixed-dose combination of inhaled bronchodilators and corticosteroids, using antibiotics, inhaled long-acting bronchodilators and corticosteroids and not using short-acting bronchodilators, other respiratory drugs and systemic corticosteroids during follow-up. Odds ratios (95% confidence intervals) for the clinical outcome associated with not discontinuing long-acting bronchodilators was 0.64 (0.50 to 0.82). In conclusion, in the real-life setting, discontinuation of inhaled long-acting bronchodilators in adults with COPD is high even after just 6\ua0months, even though persistence to these drugs reduces the risk of severe outcomes
High Expression of Cathepsin D in Non-Hodgkinâs Lymphomas Negatively Impacts on Clinical Outcome
The lysosomal protease Cathepsin D (CD) has been implicated in the homeostasis of lymphatic tissues. We investigated
whether the level of CD expression influences the progression and the clinical outcome in Non-Hodgkinâs Lymphomas (NHLs).
The expression of CD was assessed by immunohistochemistry and immunofluorescence in biopsies of Diffuse Large B Cell
Lymphomas (DLBCL, 35 cases), Follicular Lymphomas (FL, 9 cases of grade I-II plus 14 cases of grade IIIB), Chronic
Lymphocytic Leukaemias (CLL, 17 cases) and Peripheral T-cell Lymphomas (PTCL, 5 cases). CD staining showed a cytoplasmic
punctate pattern compatible with its lysosomal localization. Based on the level of CD expression and the proportion of positive
cells, lymphomas were classified as âlow expressingâ (< 20% of tumor cells) or âhighly expressingâ (â„ 20% of tumor cells).
Lymphomas highly expressing CD were associated with a worse stage (III-IV) at diagnosis (31/34 cases; p = 0.002) and with
a poor clinical outcome (i.e., partial remission and death; 28/34 cases; p = 0.03). In the subgroup of aggressive/high grade
of malignancy lymphomas (i.e., DLBCL, FL IIIB and PTCL), the Kaplan-Meier curve revealed a very low cumulative overall
survival probability (~20% at 5 year) for patients bearing a NHL with > 40% CD-positive cells compared to that of patients
bearing a NHL with < 20% CD-positive cells (~70% at 5 year). This correlation was statistically significant (log-rank test, p =
0.01). In Cox multivariate analysis CD failed to be a prognosticator independent of pathologic stage, though the hazard ratio
confirmed the association of low expression with a better survival probability. These data indicate that the presence of a high
percentage of CD-positive tumor cells negatively reflects on the progression of NHLs
Myocardial infarction and individual nonsteroidal antiâinflammatory drugs metaâanalysis of observational studies
OBJECTIVE: To conduct a systematic review of observational studies on the risk of acute myocardial infarction (AMI) with use of individual nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS: A search of Medline (PubMed) for observational studies published from 1990 to 2011 identified 3829 articles; 31 reported relative risk (RR) of AMI with use of individual NSAIDs versus nonuse of NSAIDs. Information abstracted in a standardized form from 25 publications was used for the meta-analysis on 18 independent study populations. RESULTS: Random-effects RR (95% confidence interval (CI)) was lowest for naproxen 1.06 (0.94â1.20), followed by celecoxib 1.12 (1.00â1.24), ibuprofen 1.14 (0.98â1.31), meloxicam 1.25 (1.04â1.49), rofecoxib 1.34 (1.22â1.48), diclofenac 1.38 (1.26â1.52), indometacin 1.40 (1.21â1.62), etodolac 1.55 (1.16â2.06), and etoricoxib 1.97 (1.35â2.89). Heterogeneity between studies was present. For new users, RRs (95% CIs) were for naproxen, 0.85 (0.73â1.00); ibuprofen, 1.20 (0.97â1.48); celecoxib, 1.23 (1.00â1.52); diclofenac, 1.41 (1.08â1.86); and rofecoxib, 1.43 (1.21â1.66). Except for naproxen, higher risk was generally associated with higher doses, as defined in each study, overall and in patients with prior coronary heart disease. Low and high doses of diclofenac and rofecoxib were associated with high risk of AMI, with doseâresponse relationship for rofecoxib. In patients with prior coronary heart disease, except for naproxen, duration of use â€3 months was associated with an increased risk of AMI. CONCLUSIONS: Most frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or in persons with diagnosed coronary heart disease. For diclofenac and rofecoxib, the risk was increased at low and high doses. Copyright © 2013 John Wiley & Sons, Ltd
Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies
Objective To conduct a systematic review of observational studies on the risk of acute myocardial infarction (AMI) with use of individual nonsteroidal anti-inflammatory drugs (NSAIDs). Methods A search of Medline (PubMed) for observational studies published from 1990 to 2011 identified 3829 articles; 31 reported relative risk (RR) of AMI with use of individual NSAIDs versus nonuse of NSAIDs. Information abstracted in a standardized form from 25 publications was used for the meta-analysis on 18 independent study populations. Results Random-effects RR (95% confidence interval (CI)) was lowest for naproxen 1.06 (0.94-1.20), followed by celecoxib 1.12 (1.00-1.24), ibuprofen 1.14 (0.98-1.31), meloxicam 1.25 (1.04-1.49), rofecoxib 1.34 (1.22-1.48), diclofenac 1.38 (1.26-1.52), indometacin 1.40 (1.21-1.62), etodolac 1.55 (1.16-2.06), and etoricoxib 1.97 (1.35-2.89). Heterogeneity between studies was present. For new users, RRs (95% CIs) were for naproxen, 0.85 (0.73-1.00); ibuprofen, 1.20 (0.97-1.48); celecoxib, 1.23 (1.00-1.52); diclofenac, 1.41 (1.08-1.86); and rofecoxib, 1.43 (1.21-1.66). Except for naproxen, higher risk was generally associated with higher doses, as defined in each study, overall and in patients with prior coronary heart disease. Low and high doses of diclofenac and rofecoxib were associated with high risk of AMI, with dose-response relationship for rofecoxib. In patients with prior coronary heart disease, except for naproxen, duration of use 3 months was associated with an increased risk of AMI. Conclusions Most frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or in persons with diagnosed coronary heart disease. For diclofenac and rofecoxib, the risk was increased at low and high doses. Copyright (c) 2013 John Wiley & Sons, Ltd
Persistence with inhaled corticosteroids reduces the risk of exacerbation among adults with asthma: A real-world investigation
Real-world evidence suggests that persistence with inhaled corticosteroids (ICS), the mainstay of asthma drug therapy, is generally poor. The effect of persistence with ICS on the risk of asthma exacerbation was addressed in a population-based study
- âŠ